Publications

  1. Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase III Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group Trial N0745 (Alliance). Target Oncol 2016 Dec 09 [Epub ahead of print]
    View PubMed
  2. Hubbard JM, Mahoney MR, Loui WS, Roberts LR, Smyrk TC, Gatalica Z, Borad M, Kumar S, Alberts SR. Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma: North Central Cancer Treatment Group trial N0745 (Alliance) Targeted Oncology.2016;().
  3. VanderWalde N, Jagsi R, Dotan E, Baumgartner J, Browner IS, Burhenn P, Cohen HJ, Edil BH, Edwards B, Extermann M, Ganti AK, Gross C, Hubbard J, Keating NL, Korc-Grodzicki B, McKoy JM, Medeiros BC, Mrozek E, O'Connor T, Rugo HS, Rupper RW, Shepard D, Silliman RA, Stirewalt DL, Tew WP, Walter LC, Wildes T, Bergman MA, Sundar H, Hurria A. NCCN Guidelines Insights: Older Adult Oncology, Version 2.2016. J Natl Compr Canc Netw 2016 Nov; 14 (11):1357-1370
    View PubMed
  4. Zhang BY, Jones JC, Briggler AM, Hubbard JM, Kipp BR, Sargent DJ, Dixon JG, Grothey A. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer. Clin Colorectal Cancer 2016 Sep 17 Epub 2016 Sept 17
    View PubMed
  5. Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs 2016 Feb; 34 (1):96-103 Epub 2015 Nov 18
    View PubMed
  6. Hubbard JM. Management of Colorectal Cancer in Older Adults. Clin Geriatr Med 2016 Feb; 32 (1):97-111 Epub 2015 Oct 14
    View PubMed
  7. Cheng GS, Storer B, Chien JW, Jagasia M, Hubbard JJ, Burns L, Ho VT, Pidala J, Palmer J, Johnston L, Mayer S, Crothers K, Pusic I, Lee SJ, Williams KM. Lung function trajectory in bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplant Annals of the American Thoracic Society 2016; 13 (11):1932-9
  8. Thanarajasingam G, Hubbard JM, Sloan JA, Grothey A. The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials. J Natl Cancer Inst 2015 Oct; 107 (10) Epub 2015 Aug 01
    View PubMed
  9. Pachman DR, Ruddy K, Sangaralingham LR, Grothey A, Shah ND, Beutler AS, Hubbard JM, Loprinzi CL. Calcium and Magnesium Use for Oxaliplatin-Induced Neuropathy: A Case Study to Assess How Quickly Evidence Translates Into Practice. J Natl Compr Canc Netw 2015 Sep; 13 (9):1097-101
    View PubMed
  10. Hubbard JM, Jatoi A. Incorporating biomarkers of frailty and senescence in cancer therapeutic trials. J Gerontol A Biol Sci Med Sci. 2015 Jun; 70(6):722-8. Epub 2014 Apr 26.
    View PubMed
  11. Hubbard JM, Grothey A. Colorectal cancer in 2014: progress in defining first-line and maintenance therapies. Nat Rev Clin Oncol. 2015 Feb; 12(2):73-4. Epub 2015 Jan 06.
    View PubMed
  12. Kasi PM, Thanarajasingam G, Finnes HD, Villasboas Bisneto JC, Hubbard JM, Grothey A. Chemotherapy in the Setting of Severe Liver Dysfunction in Patients with Metastatic Colorectal Cancer. Case Rep Oncol Med. 2015; 2015:420159. Epub 2015 May 21.
    View PubMed
  13. Leal AD, Hubbard J, Sargent D, Grothey A. New adjuvant trial designs in colon cancer Current Colorectal Cancer Reports 2015; 11 (6):326-34
  14. Hubbard JM, Grothey A. Colorectal cancer in 2014 : Progress in defining first-line and maintenance therapies Nature Reviews Gastroenterology and Hepatology 2015; 12 (1):19-20
  15. Hubbard JM, Cohen HJ, Muss HB. Incorporating biomarkers into cancer and aging research. J Clin Oncol 2014 Aug 20; 32 (24):2611-6 Epub 2014 July 28
    View PubMed
  16. Hubbard JM, Grothey AF, McWilliams RR, Buckner JC, Sloan JA. Physician perspective on incorporation of oncology patient quality-of-life, fatigue, and pain assessment into clinical practice. J Oncol Pract 2014 Jul; 10 (4):248-53 Epub 2014 Mar 25
    View PubMed
  17. Alliance for Clinical Trials in Oncology, Gonsalves WI, Mahoney MR, Sargent DJ, Nelson GD, Alberts SR, Sinicrope FA, Goldberg RM, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Chan E, Nair S, Berenberg JL, McWilliams RR. Patient and tumor characteristics and BRAF and KRAS mutations in colon cancer, NCCTG/Alliance N0147. J Natl Cancer Inst 2014 Jul; 106 (7) Epub 2014 June 12
    View PubMed
  18. Sridharan M, Hubbard J, Grothey A. Colorectal Cancer: How Emerging Molecular Understanding Affects Treatment Decisions Oncology. 2014 Feb 15. [Epub ahead of print]
  19. Lapid MI, Atherton PJ, Clark MM, Kung S, Richardson JW, Cheville AL, Dyrbye LN, Hubbard JM, Piderman KM, Shanafelt TD, Sloan JA, West CP, Schott DK, Rummans TA. Geriatric and non-geriatric cancer caregivers: Perceived benefits of technology. Gerontechnology. 2014; 13(2):231.
  20. Hubbard JM, Grothey A. Adolescent and young adult colorectal cancer. J Natl Compr Canc Netw. 2013 Oct 1; 11(10):1219-25.
    View PubMed
  21. Hubbard JM, Alberts SR. Alternate dosing of cetuximab for patients with metastatic colorectal cancer. Gastrointest Cancer Res 2013 Mar; 6 (2):47-55
    View PubMed
  22. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O'Connell MJ, Labianca R, Shi Q, Bleyer A, de Gramont A, Sargent D. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol 2012 Jul 1; 30 (19):2334-9 Epub 2012 May 21
    View PubMed
  23. Lewis M, Hubbard J. Treatment of liver-limited disease from colorectal cancer. Journal of Interventional Oncology. March 2012; 2(1):15-24.
  24. McWilliams RR, Mahoney MR, Sargent DJ, Nelson GD, Sinicrope F, Limburg PJ, Thibodeau SN, Grothey A, Hubbard JM, Alberts SR. A comprehensive analysis of clinical and tumor characteristics with BRAF and KRAS mutations status in adjuvant colon cancer trial N0147. J Clin Oncol 2012 Feb; 30 (4_suppl):446
    View PubMed
  25. Hubbard J, Erlichman C, Toft DO, Qin R, Stensgard BA, Felten S, Ten Eyck C, Batzel G, Ivy SP, Haluska P. Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors. Invest New Drugs 2011 Jun; 29 (3):473-80 Epub 2010 Jan 15
    View PubMed
  26. ACCENT Collaborative Group, Shi Q, Hubbard JM, Yothers GA, Andre T, Saltz L, Francini G, Bot BM, Twelves C, Buyse ME, Grothey A, Sargent DJ. Lymph node (LN) ratio (LNR) risk classification (RC) in stage III colon cancer (CC): A pooled analysis of 16,425 patients from the ACCENT database. J Clin Oncol 2011 May 20; 29 (15_suppl):3556
    View PubMed
  27. Mahoney MR, Sloan JA, Hubbard JM, Liu H, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Nair SG, Sargent DJ, Alberts SR. Quality of life (QOL) for patients treated with FOLFOX with or without cetuximab (Cmab) following complete resection of colorectal cancer (CRC): Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. J Clin Oncol 2011 May 20; 29 (15_suppl):3541
    View PubMed
  28. NCCTG, Hubbard JM, Alberts SR, Loui WS, Mahoney MR, Roberts LR, Smyrk TC, Gatalica Z, Kumar S, Dakhil SR, Flynn PJ, Lafky JM, Bury MJ. Phase I evaluation of sorafenib (SOR) and bevacizumab (BEV) as first-line therapy in hepatocellular cancer (HCC): North Central Cancer Treatment Group trial N0745. J Clin Oncol 2011 May 20; 29 (15_suppl):4116
    View PubMed
  29. Sloan JA, Mahoney MR, Sargent DJ, Hubbard JM, Liu H, Basch EM, Shields AF, Chan E, Goldberg RM, Gill S, Kahlenberg MS, Alberts SR. Was it worth it (WIWI)? Patient satisfaction with clinical trial participation: Results from North Central Cancer Treatment Group (NCCTG) phase III trial N0147. J Clin Oncol 2011 May 20; 29 (15_suppl):6122
    View PubMed
  30. Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011; 5:89-99 Epub 2011 Apr 25
    View PubMed
  31. Lewis MA, Hubbard J. Multimodal liver-directed management of neuroendocrine hepatic metastases. Int J Hepatol. 2011; 2011:452343. Epub 2011 Oct 29.
    View PubMed
  32. Hubbard J, Grothey A. Reduced chemotherapy duration: A good idea? Current Colorectal Cancer Reports. 2011; 7(3):241-5.
  33. Hubbard J, Grothey A. Antiangiogenesis agents in colorectal cancer. Curr Opin Oncol. 2010 Jul; 22(4):374-80.
    View PubMed
  34. Hubbard JM, Alberts SR. Treatment of liver-limited metastatic colorectal cancer. Cancer J. 2010 May-Jun; 16(3):235-40.
    View PubMed
  35. de Gramont, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010 Jan 20; 28(3):460-5. Epub 2009 Dec 14.
    View PubMed
  36. Hubbard J, Grothey A. Strategies for managing chemotherapy-induced sensory neuropathy. Current Colorectal Cancer Reports. 2010; 6(3):126-32.
  37. Hubbard J, Sargent D. Evidence for Cure by Adjuvant Chemotherapy in Colorectal Cancer Review. American Journal of Hematology/Oncology. 2009; 8(9):419-24.
  38. Turja J, Grothey A. Individualizing therapy for metastatic colorectal cancer. Oncology (Williston Park). 2008 Nov 30; 22(13):1479-81.
    View PubMed